What is Enumera Molecular?
Enumera Molecular is at the forefront of transforming complex diagnostic testing through its innovative EnumeraPlex platform. By facilitating liquid biopsy and high-dimensional assays, the company provides a scalable, cost-effective architecture that empowers physicians to deliver superior patient care. The firm is fundamentally democratizing precision medicine, moving away from cumbersome, expensive legacy systems toward rapid, high-precision molecular counting technologies. Their approach is designed to integrate seamlessly into existing laboratory environments, effectively lowering the barrier to entry for advanced genomic applications and ensuring that high-fidelity diagnostic data is accessible across the broader clinical landscape.
How much funding has Enumera Molecular raised?
Enumera Molecular has raised a total of $12.3M across 1 funding round:
Stock/Share Issuance
$12.3M
Stock/Share Issuance (2026): $12.3M, investors not publicly disclosed
Key Investors in Enumera Molecular
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Enumera Molecular?
With this major enterprise-level funding, Enumera Molecular is poised to transition from its current developmental phase into a period of aggressive market expansion and operational scaling. The capital will likely be deployed to enhance the manufacturing capabilities of the EnumeraPlex platform and to broaden the company's commercial footprint within the global diagnostics market. As the firm continues to refine its molecular counting technologies, the focus will shift toward securing regulatory milestones and establishing strategic partnerships with major clinical networks. By prioritizing the democratization of genomic insights, Enumera Molecular is setting the stage to become a foundational player in the next generation of personalized healthcare infrastructure.
See full Enumera Molecular company page